For older adults, the flu vaccine could look a little different this year. Last week, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 and ...

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...

New Delhi: The US Food and Drug Administration (FDA) last week approved the world’s first flu vaccine developed using messenger RNA (mRNA) technology by American pharmaceutical company Moderna, months ...

The Food and Drug Administration (FDA) late Wednesday approved the nation's first mRNA flu vaccine, manufactured by drugmaker Moderna. The agency approved the shot for two separate age groups: people ...

Moderna’s mFlusiva is the first mRNA flu vaccine approved in the U.S., but strain-selection timing and vaccine skepticism could shape its market impact. The illustration depicts the lipid-nanoparticle ...

The Food and Drug Administration has approved the first messenger RNA-based vaccine for seasonal flu, after rejecting it earlier this year. Moderna’s new seasonal flu vaccine using mRNA technology for ...

The U.S. Food and Drug Administration has approved a new flu vaccine, Moderna's mFlusiva, marking the public release of the first non-COVID-related mRNA vaccine in the U.S. Moderna's vaccine was ...

Key Takeaway: The FDA’s approval of mFLUSIVA may indicate increased commercial and strategic value of mRNA vaccine patents. On August 5, 2026, Moderna announced that the U.S. Food and Drug ...

In a somewhat surprise announcement, the Food and Drug Administration (FDA) has approved the first US influenza vaccine built on Moderna's mRNA technology that gave us one of the most administered ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna's first-of-its-kind mRNA flu vaccine has faced a bumpy road to approval amid a political climate not friendly to the ...

The FDA has approved Moderna’s mFlusiva, also known as mRNA-1010, for preventing influenza caused by the virus strains included in the vaccine. The approval covers adults ages 50 and older, although ...